Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1

• Published in: Journal of Veterinary Medical Science Vol. 85; no. 6; pp. 592 - 600
• Main Authors: KAGAWA, Yumiko, MIZUNO, Takuya, NISHIBORI, Shoma, IGASE, Masaya, UCHIDA, Kazuyuki, NAKAGAWA, Takayuki, SAKURAI, Masashi
• Format: Journal Article
• Language: English
• Published: Japan JAPANESE SOCIETY OF VETERINARY SCIENCE 2023; Japan Science and Technology Agency; The Japanese Society of Veterinary Science
• Subjects: Animals; Antibodies, Monoclonal; antibody; Apoptosis; B7-H1 Antigen; Cancer therapies; Cats; Cell death; Clinical Pathology; Clone Cells - chemistry; Clone Cells - metabolism; Cross-reactivity; feline; Flow cytometry; Immune checkpoint; Immunohistochemistry; Immunoprecipitation; Immunotherapy; Ligands; Lymph nodes; Macrophages; Mice; Monoclonal antibodies; NIH 3T3 Cells; PD-L1 protein; programmed cell death ligand 1; Tumor cells; Tumor microenvironment; Tumors; antibody; feline; immunohistochemistry; programmed cell death ligand 1; immune checkpoint

Immunotherapy is a breakthrough in human cancer therapy and has become a major concern in veterinary oncology. However, in cats, many unclear points of the tumor microenvironment exist, including immune checkpoint molecules. A reason is that very few monoclonal antibodies have been proven to react w...